Aisling O'Leary
Aisling O'Leary
School of Pharmacy & Biomedical Sciences, RCSI and National Centre for Pharmacoeconomics, St. James
Verified email at
Cited by
Cited by
Telementoring with project ECHO: a pilot study in Europe
CN Cheallaigh, A O’Leary, S Keating, A Singleton, S Heffernan, E Keenan, ...
BMJ innovations 3 (3), 2017
The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1
J Kieran, S Schmitz, A O'Leary, C Walsh, C Bergin, S Norris, M Barry
Clinical infectious diseases 56 (2), 228-235, 2013
Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland
A O’Leary, C Usher, M Lynch, M Hall, L Hemeryk, S Spillane, P Gallagher, ...
BMC research notes 8 (1), 1-10, 2015
Introduction and utilization of high priced HCV medicines across Europe; implications for the future
W De Bruijn, C Ibáñez, P Frisk, H Bak Pedersen, A Alkan, ...
Frontiers in pharmacology 7, 197, 2016
Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals
LT Nguyen, E Gray, J Dean, M Carr, J Connell, CD Gascun, LA Nguyen, ...
Antiviral therapy 20 (8), 865-869, 2015
Determinants of HIV outpatient service utilization: a systematic review
A Brennan, D Morley, AC O’Leary, CJ Bergin, M Horgan
AIDS and Behavior 19 (1), 104-119, 2015
Pharmacoeconomic evaluation in Ireland
L Tilson, A O’Leary, C Usher, M Barry
Pharmacoeconomics 28 (4), 307-322, 2010
Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
JA Kieran, S Norris, A O’Leary, C Walsh, R Merriman, D Houlihan, ...
BMC infectious diseases 15 (1), 1-9, 2015
Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients
V Gimeno-Ballester, J Mar, A O’Leary, R Adams, R San Miguel
Expert Review of Gastroenterology & Hepatology 11 (1), 85-93, 2017
Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016
C Fontela, J Castilla, R Juanbeltz, I Martínez-Baz, M Rivero, A O’Leary, ...
Postgraduate Medicine 130 (3), 317-324, 2018
The role of hepatitis C virus core antigen testing in the era of direct acting antiviral therapies: what we can learn from the protease inhibitors
LT Nguyen, E Gray, A O'Leary, M Carr, CF De Gascun, ...
PLoS One 11 (10), e0163900, 2016
Treatment of Kaposi’s sarcoma with liposomal doxorubicin
C Bergin, A O’Leary, C McCreary, K Sabra, F Mulcahy
American journal of health-system pharmacy 52 (18), 2001-2004, 1995
COVID-19 related regulatory change for pharmacists–the case for its retention post the pandemic
M Lynch, AC O'Leary
Research in Social and Administrative Pharmacy 17 (1), 1913-1919, 2021
The impact of individual patient data in a network meta‐analysis: An investigation into parameter estimation and model selection
J Leahy, A O'Leary, N Afdhal, E Gray, S Milligan, MH Wehmeyer, C Walsh
Research synthesis methods 9 (3), 441-469, 2018
High mortality during direct acting antiviral therapy for hepatitis C patients with Child’s C cirrhosis: Results of the Irish Early Access Programme
E Gray, A O’Leary, S Stewart, C Bergin, M Cannon, G Courtney, ...
Journal of Hepatology 65 (2), 446-448, 2016
Generic substitution of antiretrovirals: patients’ and health care providers’ opinions
JA Kieran, E O’Reilly, S O’Dea, C Bergin, A O’Leary
International journal of STD & AIDS 28 (12), 1239-1246, 2017
Incorporating single‐arm evidence into a network meta‐analysis using aggregate level matching: assessing the impact
J Leahy, H Thom, JP Jansen, E Gray, A O'Leary, A White, C Walsh
Statistics in medicine 38 (14), 2505-2523, 2019
Direct costs of interferon‐based and interferon‐free direct‐acting antiviral regimens for the treatment of chronic hepatitis C infection
E Gray, A O'Leary, JA Kieran, E Fogarty, T Dowling, S Norris, ...
Journal of viral hepatitis 23 (9), 677-686, 2016
Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments
J Mar, I Martínez-Baz, O Ibarrondo, R Juanbeltz, R San Miguel, I Casado, ...
Expert Review of Gastroenterology & Hepatology 13 (7), 699-708, 2019
Irish Hepatitis C Outcomes Research Network. The role of hepatitis C virus core antigen testing in the era of direct acting antiviral therapies: what we can learn from the …
LT Nguyen, E Gray, A O’Leary, M Carr, CF De Gascun
PLoS One 11 (10), 2016
The system can't perform the operation now. Try again later.
Articles 1–20